TPG Asia intends to sell its entire 14.72% stake in Sai Life Sciences for approximately ₹2,500 Crore, driven by the company's strong financial performance and growth potential in the CRDMO sector.

Target Information

TPG Asia is poised to divest its entire 14.72% stake in Sai Life Sciences Private Limited, a Hyderabad-based Contract Research, Development, and Manufacturing Organization (CRDMO). The planned sale involves approximately 3.07 crore shares, with an estimated transaction value of around ₹2,500 Crore. The shares are expected to be sold through a block deal, with a floor price set at ₹860 per share, reflecting a 5% discount from the company’s last closing price.

Sai Life Sciences has demonstrated remarkable operational growth over the past year. In the quarter ending June 2025, the company reported a net profit of ₹60 Crore, contrasting with a loss of ₹13 Crore in the previous year’s corresponding quarter. The company's revenue surged by 77% year-on-year, reaching ₹496 Crore, driven by a significant 113% increase in its CDMO segment and a robust 38% growth in Discovery revenues.

Industry Overview

The pharmaceutical industry in India is one of the fastest-growing sectors, marked by increasing demand for generic drugs and contract manufacturing services. As global companies seek to reduce co